Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Clinical outcomes and medication adherence in acute coronary syndrome patients with and without type 2 diabetes mellitus: a longitudinal analysis 2006-2011.

Cziraky MJ, Reddy VS, Luthra R, Xu Y, Wilhelm K, Power TP, Fisher MD.

J Manag Care Spec Pharm. 2015 Jun;21(6):470-7.

2.

[Two catheters for one coronary perforation].

Barbieri L, Verdoia M, Schaffer A, Marino P, De Luca G.

G Ital Cardiol (Rome). 2015 Feb;16(2):112-5. doi: 10.1714/1798.19588. Italian.

PMID:
25805096
3.

[The specific features of gout in the elderly].

Tsurko VV, Eliseeva ME, Vorob'ev PA.

Ter Arkh. 2014;86(5):50-5. Russian.

PMID:
25026802
4.

Diabetes mellitus in percutaneous coronary intervention: greater awareness is needed to predict and prevent poor outcomes.

O'Carroll G, Kearney PP.

EuroIntervention. 2014 May;10(1):13-5. doi: 10.4244/EIJV10I1A2. No abstract available.

5.

Myocardial infarction and gastro-intestinal bleeding risks associated with aspirin use among elderly individuals with type 2 diabetes.

Sirois C, Moisan J, Poirier P, Grégoire JP.

Ann Med. 2014 Aug;46(5):335-40. doi: 10.3109/07853890.2014.902636. Epub 2014 May 2.

PMID:
24785356
6.

Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.

Samoš M, Šimonová R, Kovář F, Duraj L, Fedorová J, Galajda P, Staško J, Fedor M, Kubisz P, Mokáň M.

Am J Emerg Med. 2014 May;32(5):461-5. doi: 10.1016/j.ajem.2014.01.006. Epub 2014 Jan 18.

PMID:
24560391
7.

Recurrent intraventricular thrombus six months after ST-elevation myocardial infarction in a diabetic man: a case report.

Lacalzada J, Marí B, Izquierdo MM, Sánchez-Grande A, de la Rosa A, Laynez I.

BMC Res Notes. 2013 Sep 2;6:348. doi: 10.1186/1756-0500-6-348.

8.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

PMID:
23748503
9.

Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.

Karolczak K, Kamysz W, Karafova A, Drzewoski J, Watala C.

Pharmacol Res. 2013 Aug;74:7-22. doi: 10.1016/j.phrs.2013.04.010. Epub 2013 May 7.

PMID:
23665469
10.

Primary PCI with endothelial progenitor cell-capture stent in patient with skull base fracture and aspirin allergy.

Wieczorek P, Parma R, Tendera M, Wojakowski W.

Kardiol Pol. 2013;71(2):210. doi: 10.5603/KP.2013.0023. No abstract available.

11.

Impact of adding aspirin to beta-blocker and statin in high-risk patients undergoing major vascular surgery.

Lau WC, Froehlich JB, Jewell ES, Montgomery DG, Eng KM, Shields TA, Henke PK, Eagle KA.

Ann Vasc Surg. 2013 May;27(4):537-45. doi: 10.1016/j.avsg.2012.12.001. Epub 2013 Mar 25.

PMID:
23535525
12.

Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).

Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK; BARI 2D Study Group.

J Am Coll Cardiol. 2013 Apr 30;61(17):1767-76. doi: 10.1016/j.jacc.2013.01.062. Epub 2013 Feb 28.

13.

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.

Valentine N, Van de Laar FA, van Driel ML.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD005449. doi: 10.1002/14651858.CD005449.pub2. Review.

PMID:
23152231
14.

Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.

Ye Y, Qian J, Castillo AC, Ling S, Ye H, Perez-Polo JR, Bajaj M, Birnbaum Y.

Am J Physiol Heart Circ Physiol. 2013 Jan 1;304(1):H131-41. doi: 10.1152/ajpheart.00609.2012. Epub 2012 Oct 26.

16.

Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.

Birnbaum Y, Castillo AC, Qian J, Ling S, Ye H, Perez-Polo JR, Bajaj M, Ye Y.

Cardiovasc Drugs Ther. 2012 Dec;26(6):445-56. doi: 10.1007/s10557-012-6409-x.

PMID:
22936458
17.

Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?

Serebruany VL, Atar D.

Thromb Haemost. 2012 Sep;108(3):412-4. doi: 10.1160/TH12-04-0251. Epub 2012 Jul 26.

PMID:
22836596
18.

Cardiovascular benefits of exogenous insulin.

Chaudhuri A, Dandona P, Fonseca V.

J Clin Endocrinol Metab. 2012 Sep;97(9):3079-91. doi: 10.1210/jc.2012-1112. Epub 2012 Jun 21. Review.

PMID:
22723317
19.

The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimus-eluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry.

Nakao T, Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Nobuyoshi M, Kita T, Mitsudo K.

Cardiovasc Interv Ther. 2012 Sep;27(3):161-7. Epub 2012 May 26.

PMID:
22638734
20.

Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials.

Sethi SS, Akl EG, Farkouh ME.

Curr Diab Rep. 2012 Jun;12(3):294-304. doi: 10.1007/s11892-012-0272-9. Review.

PMID:
22528594
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk